Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)

On January 23, Cantor Fitzgerald maintained its Overweight standing connected Vaxcyte Incorporated (NASDAQ:PCVX), highlighting continued advancement crossed the company’s objective pipeline. The steadfast reflected connected the topline readout from the Phase 3 OPUS-1 trial, expected successful the 4th fourth of 2026, with a planned BLA filing the pursuing year. OPUS-2 has already begun subordinate dosages, and OPUS-3 is acceptable to commencement successful Q1 of 2026. Both studies are expected to present results successful the archetypal fractional of 2027.

Pressmaster/Shutterstock.com

On January 7, Needham expert Joseph Stringer raised the terms people for Vaxcyte Incorporated (NASDAQ:PCVX) from $90 to $110 and maintained a Buy standing connected the stock. This results successful much than 100% upside astatine the prevailing level.

Stringer’s standing is backed by the inclusion of the banal connected the firm’s Conviction List, highlighting it arsenic a Top Pick for 2026 aft replacing Phathom Pharmaceuticals (PHAT). The expert shared his presumption that the powerfully affirmative Phase 2 information for VAX-31 trim hazard up of the Phase 3 readout, which is expected successful the 4th fourth of 2026. He believes the company’s pneumococcal vaccine retains best-in-class potential.

Vaxcyte Incorporated (NASDAQ:PCVX) is simply a institution processing next-generation vaccines to support against superior bacterial diseases. Currently a clinical-stage company, Vaxcyte Inc. (NASDAQ:PCVX) deploys innovative synthetic methods and precocious chemistry to nutrient complex, high-fidelity vaccines that incorporate enhanced immunological benefits.

While we admit the imaginable of PCVX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.